Compare Citius Pharmaceuticals Inc (CTXR) vs Freeport-McMoRan Inc (FCX) Price & Performance

CTXR trades at $0.765, up 6.25% today, with a bullish technical signal from moving averages. The company reported a net income margin of -823.34% for 2025 and missed EPS estimates in recent quarters. Recent news highlights strong commercial momentum for LYMPHIR, with Q2 2026 revenue of $5.6 million and expanded payer coverage.

The outlook is mixed: analyst consensus is strongly bullish (83% buy ratings), but fundamental risks are high due to persistent losses and cash burn. Upside depends on LYMPHIR's commercial success, while downside risks include funding needs and competitive pressures in oncology.

FCX trades at $66.83, down 2.98% on the day, but maintains a bullish technical trend with strong analyst support. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 expected at $0.72 EPS. Revenue remains stable around $25.9B, while net income margin improved to 11.38% in 2026. Recent news highlights operational challenges like lower copper volumes but also growth initiatives at Grasberg and Bagdad.

The outlook is positive with a consensus price target of $73.85, implying ~10% upside. Key opportunities include exposure to high copper prices and expansion projects, while risks involve production volatility, cost pressures, and reliance on commodity cycles. The stock's valuation appears elevated with a P/E of 33.93, requiring sustained earnings growth to justify further gains.